294 related articles for article (PubMed ID: 33014533)
1. Practical Approaches to Treat ED in PDE5i Nonresponders.
Cai Z; Song X; Zhang J; Yang B; Li H
Aging Dis; 2020 Oct; 11(5):1202-1218. PubMed ID: 33014533
[TBL] [Abstract][Full Text] [Related]
2. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
3. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
Cho MC; Paick JS
Ther Adv Urol; 2016 Apr; 8(2):100-17. PubMed ID: 27034723
[TBL] [Abstract][Full Text] [Related]
4. PDE5is-naïve versus non-naïve patients at first investigation for erectile dysfunction-findings from a long-term, real-life cross-sectional study.
Cilio S; Capogrosso P; Pozzi E; Belladelli F; Corsini C; Raffo M; Candela L; Fallara G; Boeri L; d'Arma A; Imbimbo C; Mirone V; Montorsi F; Salonia A
Andrology; 2024 Apr; ():. PubMed ID: 38588296
[TBL] [Abstract][Full Text] [Related]
5. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee M; Sharifi R
Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
[TBL] [Abstract][Full Text] [Related]
8. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
9. Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
Khan S; Amjad A; Rowland D
J Sex Med; 2019 Feb; 16(2):300-306. PubMed ID: 30770073
[TBL] [Abstract][Full Text] [Related]
10. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
Canguven O; Bailen J; Fredriksson W; Bock D; Burnett AL
J Sex Med; 2009 Sep; 6(9):2561-7. PubMed ID: 19627462
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use.
Romero Otero J; García Gómez B; Medina Polo J; Jiménez Alcaide E; García Cruz E; Sallent Font A; Rodríguez Antolín A
Urology; 2014 Jun; 83(6):1334-8. PubMed ID: 24745797
[TBL] [Abstract][Full Text] [Related]
12. Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care.
Costa P; Grandmottet G; Mai HD; Droupy S
J Sex Med; 2013 Jul; 10(7):1850-60. PubMed ID: 23679019
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
15. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders.
Musa ZS; El-Assmy A; Shokry AM; Shokeir AA; Zween T; Al-Kenawy MR
Arab J Urol; 2020; 18(1):54-58. PubMed ID: 32082635
[No Abstract] [Full Text] [Related]
17. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
Cai Z; Zhang J; Li H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
[TBL] [Abstract][Full Text] [Related]
18. Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications.
Aversa A; Duca Y; Condorelli RA; Calogero AE; La Vignera S
Front Endocrinol (Lausanne); 2019; 10():225. PubMed ID: 31110491
[TBL] [Abstract][Full Text] [Related]
19. Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors.
Tsai CC; Wang CJ; Lee YC; Kuo YT; Lin HH; Li CC; Wu WJ; Liu CC
Am J Mens Health; 2017 Nov; 11(6):1781-1790. PubMed ID: 28884638
[TBL] [Abstract][Full Text] [Related]
20. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
